This site is intended for healthcare professionals only
LoginRegister
Palamur Biosciences Faces USFDA Warning for Multiple GLP Compliance FailuresUSFDA completes audit at Jubilant HollisterStier 2 Washington facilities
Torsemide, Dapagliflozin FDC not rational: CDSCO Panel Rejects Syngenes Proposal for BA/BE studyTorsemide, Dapagliflozin FDC not rational: CDSCO Panel Rejects Syngene's Proposal for BA/BE study
Eli Lilly Announces USD 3.5 Billion US Manufacturing Facility for Next-Gen Obesity DrugsEli Lilly Kisunla approved in Japan for early Symptomatic Alzheimer's disease
Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial MetricsBiocon Biologics announces New Dermatology data to be presented at EADV Congress 2024
Granules India unveils Mobile Cancer Screening Unit at AIG HospitalsGranules India unveils Mobile Cancer Screening Unit at AIG Hospitals
Natco Pharma announces resignation of Sourav Chakraborty, Associate Vice President - Sales & Marketing, Crop Health Sciences DivisionNatco Pharma announces resignation of Sourav Chakraborty, Associate Vice President - Sales &...
Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag InternationalSubmit safety data on South Asian subjects with Plaque Psoriasis: CDSCO Panel Tells Johnson &...
RocheRoche launches cobas Respiratory flex test to detect up to 12 most common respiratory viruses
Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indicationLung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional...
Merck in Talks to Acquire Revolution Medicines in USD 28-32 Billion Oncology DealMerck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of...
Eli Lilly in Talks to Acquire Ventyx Biosciences in USD 1 Billion-Plus DealEli Lilly planning expansion of research centre in India: CEO David Ricks
Merck in Talks to Acquire Revolution Medicines in USD 28-32 Billion Oncology DealUSFDA nod to Merck KEYTRUDA plus Pemetrexed, Platinum Chemotherapy for Unresectable Advanced or...
X